{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-010239","form_type":"8-K","ticker":"PTN","cik":"0000911216","company_name":"PALATIN TECHNOLOGIES INC","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.995913+00:00","generated_at":"2026-06-12T03:29:43.121735+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Palatin: Fosun reports first Vyleesi sale in China; Kwangdong completes Phase 3 enrollment","bullets":["Fosun dispensed first Vyleesi prescription in Hainan Province, China.","Kwangdong completed Phase 3 enrollment: 193 patients enrolled, 180 completed (93%).","Data from Korea trial expected by year end; potential MFDS submission in H1 2024.","Palatin eligible for up to $92.5M in milestones from Fosun plus royalties; $3M milestone from Kwangdong.","Vyleesi is only FDA-approved as-needed HSDD treatment; Palatin reported six consecutive quarters of double-digit prescription growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-010239","json":"https://secwatch.observer/filing/0001654954-23-010239.json","markdown":"https://secwatch.observer/filing/0001654954-23-010239.md","text":"https://secwatch.observer/filing/0001654954-23-010239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/911216/000165495423010239/0001654954-23-010239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/911216/000165495423010239/ptn_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T03:29:43.121735+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}